LAS VEGAS, Oct. 29, 2020 /PRNewswire/ -- The Rheumatoid Arthritis market report delivers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan for the study period of 2017-2030.
Few of the key highlights from the report:
To know how the trends will be impacting the market, click on the link to download the sample: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory autoimmune disease and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. Even after years of research, the cause of rheumatoid arthritis is still unknown. Rheumatoid Arthritis symptoms include joint pain, stiffness, swelling, and decreased movement of the joints. Rheumatoid arthritis diagnosis is done by a combination of patient's symptoms, results of doctor's examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of Rheumatoid Arthritis -specific autoantibodies. Rheumatoid Arthritis has a predilection to affect women, that's why the incidence and prevalence rates in women for RA is 2- 3 times more as compared to men. The total prevalent cases of Rheumatoid Arthritis in the 7MM were observed to be 4,356,793 in 2017 which are estimated to rise during the study period (2017?2030). The United States accounted for the highest number of cases in the 7MM.
The report provides an in-depth historical and forecasted analysis of Rheumatoid Arthritis Epidemiology segmented by:
Rheumatoid Arthritis Treatment Market
The Rheumatoid Arthritis treatment paradigm includes medicine, supportive treatment and surgery. Currently, there are three primary treatment options for severe and advancing Rheumatoid Arthritis which include DMARDs, NSAIDs, and corticosteroids. Rheumatoid market consists of many different drug target agents forming different drug classes. Conventional DMARDs are a group of drugs (i.e. methotrexate, leflunomide, hydroxychloroquine, sulfasalazine) that have been shown to affect the underlying cause of RA by damping down over-activity of the immune system, which helps to ease pain, swelling and stiffness, and prevent changes occurring within the joint. Among csDMARDS, methotrexate (MTX) is considered as a part of the first treatment strategy. MTX remains the anchor drug in RA; along with usage as monotherapy, it is also the basis for combination therapies, either with GC or with other csDMARDs, bDMARDs or tsDMARDs.Patients refractory to csDMARDS or with severe symptoms usually treated with a wide variety of biologics DMARDs classes like anti-TNF, T cell inhibitor, B cell Inhibitor, Interleukin Inhibitors and targeted synthetic DMARDs like JAK Inhibitors. The drug classes include blockbusters Anti-TNF (Etanercept, Infliximab, Adalimumab, Certolizumab-pegol) JAK inhibitors (tofa citinib, baricitinib, upadacitinib, Peficitinob) B-cell inhibitors (Rituximab), Interleukin Inhibitors (Tocilizumab, Sarilumab), T-cell inhibitors (Abatacept), DMARDs, other novel inhibitors, etc.
Biological DMARDs showed promising results in treating RA patients and market penetration is expected to be more in the future and this class is expected to drive the growth of the market. Oral classes such as JAKi and upcoming BTKi due to patient convenient RoA are also expected to contribute to the Rheumatoid Arthritis market growth. The market for Rheumatoid Arthritis possesses fierce competition but still, there is a high demand for new therapies having similar or better efficacy, however, improved safety profile as well as patient adherence. Because of high competition, the new entrants are expected to be met with some resistance and will experience slow uptake, as the market is currently dominated by the anti-TNFs and entry of biosimilars will further pose significant challenges to new and upcoming treatment. It goes without saying that the dynamics of the Rheumatoid Arthritis market is expected to change because of the launch of emerging therapies, companies like GlaxoSmithKline [Otilimab (MOR103/GSK3196165)], Taisho Pharmaceutical [Ozoralizumab (TS-152)], Gilead and Galapagos NV [Filgotinib (GS-6034; Jyseleca)], and R-Pharm (Olokizumab) with their key candidates are in registrational or late clinical-stage. In addition to this, companies like Merck KGaA (Evobrutinib), Pfizer (PF-06650833, and PF-06651600), Roche (Fenebrutinib), and several others in phase II clinical development stage with their investigational candidates.
As many potential therapies are being investigated for the management of Rheumatoid Arthritis, it is for sure that the treatment space will experience a significant impact during the forecast period of 2020?2030.
As the emerging drugs will be entering the market, to know what will be their impact on the existing market, which drug will be a blockbuster, and for which line of treatment these drugs will be used? Download the RA Report to know more:- https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market
Scope of the Report
Table of Contents
1. Key Insights |
2. Executive Summary of Rheumatoid Arthritis |
3. SWOT Analysis of Rheumatoid Arthritis |
4. Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Country |
5. Rheumatoid Arthritis Market Share (%) Distribution Overview at a Glance: By Class |
6. Rheumatoid Arthritis Disease Background and Overview |
7. Rheumatoid Arthritis Epidemiology and Patient Population |
8. Rheumatoid Arthritis Epidemiology Scenario: 7MM |
9. The United States Rheumatoid Arthritis Epidemiology |
10. EU-5 Rheumatoid Arthritis Epidemiology |
10.1. Germany |
10.2. France |
10.3. Italy |
10.4. Spain |
10.5. The United Kingdom |
11. Japan Rheumatoid Arthritis Epidemiology |
12. Current Rheumatoid Arthritis Treatment Practices |
12.1. Medications |
12.2. Supportive Treatment |
12.3. Surgery |
12.4. Treatment Algorithm |
12.5. Guideline of Rheumatoid Arthritis |
13. Unmet Needs |
14. Patient Journey of Rheumatoid Arthritis |
15. Key Endpoints in Rheumatoid Arthritis Clinical Trials |
16. Rheumatoid Arthritis Marketed Therapies |
16.1. Marketed Therapies Key Cross |
16.2. Olumiant (Barticinib): Eli Lilly and Company/Incyte Corporation |
16.3. Rinvoq (Upadacitinib): AbbVie |
16.4. Xeljanz (Tofacitinib): Pfizer/PV PRISM CV |
16.5. Remicade (Infliximab): Janssen Biotech (Centocor) |
16.6. Enbrel (Etanercept): Immunex/Amgen |
16.7. Rituxan/MabThera (Rituximab): Genentech/Biogen |
16.8. Certolizumab-pegol (Cimzia): UCB Inc. |
16.9. Golimumab (Simponi): Janssen Biotech |
16.10. Humira (adalimumab): AbbVie |
16.11. Orencia (Abatacept): Bristol Myers Squibb |
16.12. Smyraf (Peficitinib): Astella Pharma |
16.13. Actemra (Tocilizumab): Roche |
16.14. Kineret (Anakinra): Swedish Orphan Biovitrium (SOBI) |
16.15. Kevzara (Sarilumab): Regeneron and Sanofi |
17. Rheumatoid Arthritis Emerging Therapies |
17.1. Key Cross |
17.2. GSK3196165 (otilimab/MOR103): GlaxoSmithKline |
17.3. Filgotinib (GS-6034; GLPG0634; Jyseleca): Gilead and Galapagos NV |
17.4. Olokizumab: R-Pharm |
17.5. TS-152 (Ozoralizumab): Taisho Pharmaceuticals |
17.6. ATI-450 (CDD-450): Aclaris Therapeutics |
17.7. VIB4920: Viela Bio |
17.8. Branebrutinib: Bristol Myers Squibb |
17.9. ABBV-3373 and ABBV-154: AbbVie |
17.10. Dekavil (F8IL10): Pfizer/Philogen |
17.11. PF-06651600 (Ritlecitinib): Pfizer |
17.12. JTE 051: Akros Pharma/Japan Tobacco |
17.13. Evobrutinib (M2951): Merck KGaA |
17.14. PF-06650833: Pfizer |
17.15. Fenebrutinib (GDC-0853, RG7845): Genentech (subsidiary of Roche) |
17.16. MPC-300-IV (Allogeneic Mesenchymal Precursor Cells): Mesoblast |
17.17. Bimekizumab: UCB Pharma/PRA HEALTH SCIENCES |
17.18. Namilumab (IZN-101; AMG203): Izana Bioscience/Takeda |
17.19. ABX464: Abivax S.A. |
17.20. HB-AdMSCs: Hope Biosciences |
17.21. SKI-O-703: Genosco (Oscotec) |
18. Conjoint Analysis of Rheumatoid Arthritis |
19. Rheumatoid Arthritis Seven Major Market Analysis |
20. 7MM Rheumatoid Arthritis Market Size |
21. United States Rheumatoid Arthritis Market Size |
22. EU-5 Rheumatoid Arthritis Market Size |
22.1. Germany Market Size |
22.2. France Market Size |
22.3. Italy Market Size |
22.4. Spain Market Size |
22.5. United Kingdom Market Size |
23. Japan Rheumatoid Arthritis Market Size |
24. Market Access and Reimbursement of Rheumatoid Arthritis Therapies |
25. Rheumatoid Arthritis Market Drivers |
26. Rheumatoid Arthritis Market Barriers |
27. Appendix |
28. DelveInsight Capabilities |
29. Disclaimer |
30. About DelveInsight |
Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market
Related Reports
- Rheumatoid Arthritis - Epidemiology Forecast to 2030
DelveInsight's Rheumatoid Arthritis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Rheumatoid Arthritis.
- Rheumatoid Arthritis - Pipeline Insights, 2020
Rheumatoid Arthritis (RA) - Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Rheumatoid Arthritis (RA) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
[email protected]
+91-9650213330
DelveInsight
SOURCE DelveInsight Business Research, LLP
These press releases may also interest you
|